Mostrando 6 resultados de: 6
Publisher
Biomedicine and Pharmacotherapy(1)
European Eating Disorders Review(1)
Expert Opinion on Investigational Drugs(1)
Frontiers in Aging Neuroscience(1)
Journal of Molecular Medicine(1)
Área temáticas
Enfermedades(5)
Farmacología y terapéutica(2)
Problemas sociales y servicios a grupos(2)
Salud y seguridad personal(2)
Fisiología humana(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(6)
ODS 2: Hambre cero(5)
ODS 17: Alianzas para lograr los objetivos(1)
Origen
scopus(6)
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusProtein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders
ReviewAbstract: Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct nPalabras claves:Alzheimer's disease, insulin receptor, neurodegenerative diseases, neuroinflammation, Neurological disorders, PTP1B, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Bulló M., Cano A., Carrasco M., Ettcheto M., Folch J., Fortuna A., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusPsychological and metabolic risk factors in older adults with a previous history of eating disorder: A cross-sectional study from the Predimed-Plus study
ArticleAbstract: Goals: To explore affective and cognitive status, later in life, in individuals with and without prePalabras claves:Cardiovascular Risk, depressive symptoms, eating disorder, Metabolic syndrome, neuropsychological profileAutores:Abete I., Alonso-Gómez Á.M., Babio N., Baenas-Soto I., Basterra-Gortari F.J., Bello-Mora M.C., Bernal-López M.R., Bulló M., Cárdenas J.J., Casas R.M., Cavanillas A.B., Corella D., Cuenca-Royo A.M., Daimiel L., Delgado-Rodríguez M., Díaz-López A., Estruch R., Fernández‐aranda F., Fitó M., Forcano-Gamazo L., García-Arellano A., García-de-la-Hera M., García-Ríos A., Gómez-Pérez A.M., González J.I., Konieczna J., Lapetra J., Lozano-Madrid M.d.E., Martínez J.A., Matía-Martín P., Miranda J.L., Pinto X., Razquin C., Romaguera D., Ros E., Roser Granero, Ruiz-Canela M., Salas-Salvadó J., Salaverria-Lete I., Sánchez V.M., Sanchez-Villegas A., Sorlí J.V., Torre R.d.l., Tur J.A., Valenzuela-Guerrero S., Vidal J., Vintró-Alcaraz C., Vioque J., Wärnberg J., Zulet M.d.l.Á.Fuentes:scopusTriple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease
ArticleAbstract:Palabras claves:Alzheimer’s disease, glucagon, glucagon-like peptide, glucose-dependent insulinotropic peptide, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Castro-Torres R.D., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sureda F.X., Verdaguer E., Zárate C.B.Fuentes:scopusType 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study
ArticleAbstract: This study cross-sectionally examines in the elderly population: (a) the association of type 2 diabePalabras claves:Autores:Abete I., Alonso-Gómez Á.M., Barragán R., Buil-Cosiales P., Bulló M., Castañer-Niño O., Cavanillas A.B., Corella D., Cuenca-Royo A.M., Daimiel L., Díaz-López A., Estruch R., Fernández‐aranda F., Gaforio J.J., García-de-la-Hera M., García-Ríos A., Lapetra J., Lopez-Miranda J., Lozano-Madrid M.d.E., Mallorquí-Bague N., Martínez J.A., Martínez-González M.A., Matía-Martín P., Murcia S.J., Pinto X., Romaguera D., Ros E., Roser Granero, Ruiz-Canela M., Salas-Salvadó J., Sánchez V.M., Serra-Majem L., Tinahones F.J., Toledo E., Torre R.d.l., Tur J.A., Vázquez C., Vidal J., Vioque J., Wärnberg J., Yáñez A.M.Fuentes:scopusc-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments
ArticleAbstract: Abstract: The development of metabolic alterations like insulin resistance has been associated withPalabras claves:c-Jun N-terminal Kinase 1, Cognitive impairments, high-fat dietAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Casadesús G., Castro-Torres R.D., Eritja À., Espinosa-Jimenez T., Ettcheto M., Folch J., Olloquequi J., Verdaguer E., Zárate C.B.Fuentes:scopus